Comparative Pharmacology
Head-to-head clinical analysis: ALKERGOT versus TOSYMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERGOT versus TOSYMRA.
ALKERGOT vs TOSYMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine tartrate acts as a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also blocks alpha-adrenergic receptors. It causes vasoconstriction of intracranial blood vessels and reduces extravasation of plasma proteins, thereby alleviating migraine pain. Caffeine enhances ergotamine absorption and may provide additional vasoconstrictive effects.
Sumatriptan is a selective agonist of serotonin (5-HT1B/1D) receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
Oral: Ergotamine 1mg/caffeine 100mg combination: 2 tablets at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
10 mg intranasally as a single dose, may repeat once after 24 hours if needed. Maximum 2 doses in 7 days.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours. Clinical context: Short half-life supports use for acute migraine attacks; frequent dosing may be needed for prolonged symptoms.
Terminal elimination half-life approximately 2.5 hours; clinically relevant for dosing every 4-6 hours.
Primarily hepatic metabolism followed by biliary and fecal excretion (approx. 90%). Less than 2% is excreted unchanged in urine. Renal elimination of metabolites accounts for about 10%.
Renal excretion of unchanged drug and metabolites; 70% recovered in urine as parent and metabolites, 30% in feces.
Category C
Category C
Antimigraine Agent
Antimigraine Agent